Title: The Innovations of Muh-Hwan Su
Introduction
Muh-Hwan Su is a notable inventor based in China, recognized for his contributions to the field of pharmaceuticals. He has focused on developing compositions that target amyloid beta peptide-associated diseases. His work is significant in the ongoing battle against conditions related to amyloid beta peptides.
Latest Patents
Muh-Hwan Su has recently developed two notable patents. The first is a pharmaceutical composition for preventing or treating amyloid beta peptide-associated diseases or conditions. This composition contains isoacteoside to acteoside, which is effective in inhibiting the formation, accumulation, or aggregation of amyloid beta peptides. The weight ratio of isoacteoside to acteoside is between 4:1 to 1:4. The second patent involves the use of isoacteoside or a pharmaceutically acceptable salt thereof as an inhibitor of the production, accumulation, or aggregation of amyloid beta peptide. This innovation has potential applications in preventing or treating diseases or symptoms associated with amyloid beta peptide.
Career Highlights
Muh-Hwan Su is currently associated with Sinphar Tian-li Pharmaceutical Co., Ltd., where he continues to advance his research and development efforts. His work has garnered attention for its potential impact on treating neurodegenerative diseases.
Collaborations
Some of his notable coworkers include Hang-Ching Lin and Young-Ming Huang, who contribute to the collaborative efforts in their research projects.
Conclusion
Muh-Hwan Su's innovative work in pharmaceutical compositions showcases his commitment to addressing critical health challenges. His contributions are paving the way for advancements in the treatment of amyloid beta peptide-associated diseases.